search
Back to results

A New Screening Strategy for 2019 Novel Coronavirus Infection

Primary Purpose

Novel Coronavirus Infection Pneumonia

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Standard screening strategy
New screening strategy
Sponsored by
Affiliated Hospital to Academy of Military Medical Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Novel Coronavirus Infection Pneumonia

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Who agree to participate in the study and sign written informed consent

Exclusion Criteria:

  • Confirmed NCIP patients

Sites / Locations

  • the Fifth Medical Center of Chinese PLA General Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Screening participants

Arm Description

Outcomes

Primary Outcome Measures

Screening accuracy
The screening accuracy of the two screening strategies were calculated and compared.

Secondary Outcome Measures

Cost-effectiveness analysis
The costs of the two screening strategies were recorded. Cost-effectiveness analysis were performed and compared.

Full Information

First Posted
February 20, 2020
Last Updated
February 21, 2020
Sponsor
Affiliated Hospital to Academy of Military Medical Sciences
Collaborators
Beijing 302 Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04281693
Brief Title
A New Screening Strategy for 2019 Novel Coronavirus Infection
Official Title
Identification of a New Screening Strategy for 2019 Novel Coronavirus Infection
Study Type
Interventional

2. Study Status

Record Verification Date
February 2020
Overall Recruitment Status
Unknown status
Study Start Date
February 2020 (Anticipated)
Primary Completion Date
March 2020 (Anticipated)
Study Completion Date
March 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Affiliated Hospital to Academy of Military Medical Sciences
Collaborators
Beijing 302 Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Since Dec 2019, over 70000 novel coronavirus infection pneumonia (NCIP) patients were confirmed. 2019 novel coronavirus (2019 nCoV) is a RNA virus, which spread mainly from person-to-person contact. Most of the symptoms are non-specific, including fever, fatigue, dry cough. Sever NCIP patients may have shortness of breath and dyspnea, and progress to acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS). The mortality is reported to be around 2.3%. Thus, early detection and early treatment is very important to the improvement of NCIP patients' prognosis. At present, NCIP RNA detection of pharyngeal swab specimen by RT-PCR is recommended. However, due to the universal susceptibility to 2019 nCoV in general population and limited number of NCIP RNA detection kits available, to identify an efficient screening strategy is urgently needed. This study aim to develop and validate the diagnostic accuracy and screening efficiency of a new NCIP screening strategy, which can benefit the disease prevention and control.
Detailed Description
This clinical trial is designed to compare the screen accuracy and efficiency of two screening strategies. Considering that the general population is susceptible to 2019 nCoV, a great number of people need to be screened for NCIP. The new screening strategy of minipool testing may not only obtain a comparable accuracy to the standard individual testing, but also save time and money, which may benefit the current clinical practice.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Novel Coronavirus Infection Pneumonia

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
230 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Screening participants
Arm Type
Experimental
Intervention Type
Diagnostic Test
Intervention Name(s)
Standard screening strategy
Intervention Description
The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by individual testing.
Intervention Type
Diagnostic Test
Intervention Name(s)
New screening strategy
Intervention Description
The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by minipool testing.
Primary Outcome Measure Information:
Title
Screening accuracy
Description
The screening accuracy of the two screening strategies were calculated and compared.
Time Frame
1 month
Secondary Outcome Measure Information:
Title
Cost-effectiveness analysis
Description
The costs of the two screening strategies were recorded. Cost-effectiveness analysis were performed and compared.
Time Frame
1 month

10. Eligibility

Sex
All
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Who agree to participate in the study and sign written informed consent Exclusion Criteria: Confirmed NCIP patients
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Xiaotian Sun
Phone
+86-01066823480
Email
xiaotian-sun@hotmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Zheng Lu
Phone
+86-01066823480
Email
13818223446@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yan Liu
Organizational Affiliation
Beijing 302 Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
the Fifth Medical Center of Chinese PLA General Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100071
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yan Liu, Ph.D.
Phone
010-66947473
Email
13911798288@163.com

12. IPD Sharing Statement

Citations:
PubMed Identifier
32031570
Citation
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585. Erratum In: JAMA. 2021 Mar 16;325(11):1113.
Results Reference
background
PubMed Identifier
32064853
Citation
Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151. doi: 10.3760/cma.j.issn.0254-6450.2020.02.003. Chinese.
Results Reference
background

Learn more about this trial

A New Screening Strategy for 2019 Novel Coronavirus Infection

We'll reach out to this number within 24 hrs